Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia pos (Q46505730)
Jump to navigation
Jump to search
scientific article published on 3 July 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia pos |
scientific article published on 3 July 2008 |
Statements
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia (English)
A Shimoni
M Leiba
M Schleuning
G Martineau
M Renaud
E Ribakovski
P le Coutre
R Arnold